Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial

American Heart Journal

Volumn 154, Issue 6, 2007, Pages

  Morrow, David A ^a   Antman, Elliott M ^a   Murphy, Sabina A ^a   Qin, Jie ^a   Ruda, Mikhail ^b   Guneri, Sema ^c   Jacob, Ashok Joseph ^d   Budaj, Andrzej ^e   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c Dokuz Eyful Universitesi   (Turkey)

^d ST JOHN'S HOSPITAL   (United Kingdom)

^e MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 36148931835     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.07.027     Document Type: Article

References (34)

1. Howard B.V., Rodriguez B.L., Bennett P.H., et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: Epidemiology. Circulation 105 (2002) e132-e137
2. Mak K.H., Moliterno D.J., Granger C.B., et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 30 (1997) 171-179
3. Berger A.K., Breall J.A., Gersh B.J., et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol 87 (2001) 272-277
4. Aguilar D., Solomon S.D., Kober L., et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110 (2004) 1572-1578
5. Grundy S.M., Benjamin I.J., Burke G.L., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146
6. Norhammar A., Malmberg K., Ryden L., et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 24 (2003) 838-844
7. Sabatine M.S., and Braunwald E. Will diabetes save the platelet blockers?. Circulation 104 (2001) 2759-2761
8. The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
9. Antman E.M., Louwerenburg H.W., Baars H.F., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105 (2002) 1642-1649
10. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
11. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149 (2005) 217-226
12. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) E1-E211
13. Morrow D.A., Antman E.M., Charlesworth A., et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 (2000) 2031-2037
14. Vaccarino V, Parsons L, Every NR, et al. Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction. The National Registry of Myocardial Infarction 2 Participants. Am J Cardiol 2000;85:1486-9; A7.
15. Conaway D.G., O'Keefe J.H., Reid K.J., et al. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 96 (2005) 363-365
16. Norhammar A., Tenerz A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
17. Bartnik M., Malmberg K., Norhammar A., et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 25 (2004) 1990-1997
18. Mukamal K.J., Nesto R.W., Cohen M.C., et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 24 (2001) 1422-1427
19. Levantesi G., Macchia A., Marfisi R., et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 46 (2005) 277-283
20. Suleiman M., Hammerman H., Boulos M., et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 111 (2005) 754-760
21. Pinto D.S., Skolnick A.H., Kirtane A.J., et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 46 (2005) 178-180
22. Moreno P.R., and Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44 (2004) 2293-2300
23. Libby P., Nathan D.M., Abraham K., et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111 (2005) 3489-3493
24. Auwerx J., Bouillon R., Collen D., et al. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8 (1988) 68-72
25. Calles-Escandon J., Mirza S.A., Sobel B.E., et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 47 (1998) 290-293
26. Sagel J., Colwell J.A., Crook L., et al. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 82 (1975) 733-738
27. Shechter M., Merz C.N., Paul-Labrador M.J., et al. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 35 (2000) 300-307
28. Zumbach M., Hofmann M., Borcea V., et al. Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes 105 (1997) 206-212
29. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 (2003) 973-977
30. Deedwania P.C. Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. Cardiol Clin 22 (2004) 505-509
31. Pradhan A.D., Manson J.E., Rifai N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
32. Roffi M., Chew D.P., Mukherjee D., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104 (2001) 2767-2771
33. Bartnik M., Ryden L., Ferrari R., et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25 (2004) 1880-1890
34. Sabatine M.S., Morrow D.A., Mohanavelu S., et al. Efficacy and safety of enoxaparin vs. UFH in patients with ST-elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol 49 (2007) 2256-2263